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Objective. Human osteoarthritis (OA) is charac-
terized by a pathologic shift in articular cartilage ho-
meostasis toward the progressive loss of extracellular
matrix (ECM). The purpose of this study was to inves-
tigate the ability of rAAV-mediated SOX9 overexpres-
sion to restore major ECM components in human OA
articular cartilage.
Methods. We monitored the synthesis and content
of proteoglycans and type II collagen in 3-dimensional
cultures of human normal and OA articular chondro-
cytes and in explant cultures of human normal and OA
articular cartilage following direct application of a
recombinant adeno-associated virus (rAAV) SOX9 vec-
tor in vitro and in situ. We also analyzed the effects of
this treatment on cell proliferation in these systems.
Results. Following SOX9 gene transfer, expression
levels of proteoglycans and type II collagen increased
over time in normal and OA articular chondrocytes in
vitro. In situ, overexpression of SOX9 in normal and OA
articular cartilage stimulated proteoglycan and type II
collagen synthesis in a dose-dependent manner. These
effects were not associated with changes in chondrocyte
proliferation. Notably, expression of the 2 principal
matrix components could be restored in OA articular
cartilage to levels similar to those in normal cartilage.
Conclusion. These data support the concept of
using direct, rAAV-mediated transfer of chondrogenic
genes to articular cartilage for the treatment of OA in
humans.
Osteoarthritis (OA) is a progressive disease that
affects diarthrodial joints and is mainly characterized by
a gradual deterioration of the articular cartilage. A
disturbed balance in cartilage metabolism is thought to
play an important role in the pathogenesis of OA and to
be a key factor in determining its progression. Over the
course of OA, the cartilage loses major components of
its extracellular matrix (ECM), such as proteoglycans
and type II collagen (1). Proinflammatory cytokines,
such as interleukin 1 (IL-1) and tumor necrosis factor ,
produced locally by the inflamed synovium likely con-
tribute to the pathophysiology of OA (2). Articular
chondrocytes are the focus of OA because of pathologic
changes in their gene expression pattern (3), the loss of
their capacity to synthesize cartilage-specific matrix mol-
ecules, and their increased production of matrix-
degrading enzymes (4).
Despite various therapeutic options, including
systemic nonsteroidal antiinflammatory drugs, local
corticosteroids, physical therapy, regular exercise, use of
orthopedic appliances, or with the advent of disease- and
structure-modifying drugs, the management of OA re-
mains an unresolved problem, especially for patients
who are too young to undergo endoprosthetic total joint
replacement. The difficulty in treating OA is largely due
to its slow and irreversible progression and to the limited
intrinsic ability of the cartilage to reequilibrate its nat-
ural components. Application of therapeutic genes to
OA cartilage may offer potent alternatives for reestab-
Drs. Cucchiarini and Madry’s work was supported by the
German Research Society (DFG grants CU 55/1-1 and CU 55/1-2) and
the German Osteoarthritis Foundation. Dr. Kohn’s work was sup-
ported by the German Osteoarthritis Foundation.
1Magali Cucchiarini, PhD, Tanja Thurn, BS, Anja Weimer,
BS, Dieter Kohn, MD, Henning Madry, MD: Saarland University
Medical Center, Homburg, Germany; 2Ernest F. Terwilliger, PhD:
Harvard Institutes of Medicine and Beth Israel Deaconess Medical
Center, Boston, Massachusetts.
Address correspondence and reprint requests to Magali Cuc-
chiarini, PhD, Laboratory for Experimental Orthopaedics, Depart-
ment of Orthopaedics and Orthopaedic Surgery, Saarland University
Medical Center, D-66421 Homburg, Germany. E-mail: mmcucchiarini
@hotmail.com.
Submitted for publication March 9, 2006; accepted in revised
form September 21, 2006.
158
lishing the structural integrity of the damaged cartilage
architecture.
Most of the current approaches to restoring the
physiologic balance in injured articular cartilage are
based on the delivery of factors that modulate the
metabolic functions of chondrocytes, such as agents that
counteract the processes of matrix degradation or ones
that enhance the synthesis of matrix components. Pro-
tective effects of an IL-1 receptor antagonist (IL-1Ra)
sequence against IL-1–induced cartilage breakdown
have been documented in experimental models ex vivo
(5,6) and in vivo (7,8). The transfer of the gene for a
heat-shock protein (Hsp70) was also shown to afford
protection against cellular injuries in chondrocytes (9).
Alternatively, the delivery of sequences encoding for
growth and enzymatic factors can potentially stimulate
cartilage anabolism in vitro and in situ, such as insulin-
like growth factor 1 (IGF-1) (10), fibroblast growth
factor 2 (FGF-2) (11), bone morphogenetic protein 7
(BMP-7) (12), transforming growth factor  (TGF)
(13), and glucuronosyltransferase I (14). However, ap-
plication of external stimuli to damaged articular carti-
lage has not yet proved sufficient in fully reestablishing
an original cartilage surface, and little is known about
the effects on human OA cartilage. Other avenues of
research may thus have value in the identification of
supplementary treatments for OA.
Strategies to correct the altered gene expression
patterns in OA chondrocytes may prove beneficial in
readjusting the disturbed cartilage homeostasis. Tran-
scription factors are key regulators of cartilage metabo-
lism since they stimulate chondrogenesis in physiologic
and pathologic conditions. Among them, SOX9, a mem-
ber of the sex-determining region Y–type high mobility
group box family of DNA binding proteins, plays critical
roles in the regulation of skeletal and cartilage forma-
tion (15) and chondrocyte differentiation (16). SOX9 is
expressed during embryonic development in a pattern
that closely parallels that of cartilage matrix synthesis
(17) and exerts its properties by activating the gene for
type II collagen and other cartilage-specific genes (17–
20). Notably, the levels of SOX9 expression decline in
OA cartilage (21,22). Modulation of the chondrocyte
phenotype in OA cartilage by genetically modifying the
levels of intracellular SOX9 expression might be advan-
tageous in shifting the disrupted balance toward the
synthesis of ECM components and contribute to the
reproduction of an original articular cartilage surface.
A prerequisite for the development of an appli-
cable gene treatment against OA is the ability of the
gene vehicle to mediate the efficient and sustained
expression of a candidate agent in order to counterbal-
ance the progression of the disease. Recombinant
adeno-associated virus (rAAV) vectors are particularly
well suited for this purpose because they can transfer
genes into human OA chondrocytes in vitro and in situ
with high efficiencies and for extended periods of time
(23–25). The rAAV vectors are derived from a
replication-defective human parvovirus that is non-
pathogenic in humans. The rAAV can transduce both
dividing and nondividing cells, such as chondrocytes, and
they drive transgene expression from highly stable epi-
somes, which can persist for months to years (26). In
addition, rAAV exhibit a reduced immunogenicity due
to the complete removal of the viral protein coding
sequences in the recombinant genome. These features
are in marked contrast with the properties of other
classes of vectors (27), such as retroviral vectors, which
necessitate the division of the target cells (28), or
adenoviral vectors, which generally mediate only short-
term transgene expression (29).
In the present study, we tested the hypothesis
that SOX9 overexpression via rAAV promotes the syn-
thesis of proteoglycans and type II collagen in human
OA chondrocytes in vitro and in cartilage explants in
situ. We also evaluated whether application of the SOX9
vector restores the cartilage matrix in human OA carti-
lage as compared with normal cartilage.
MATERIALS AND METHODS
Reagents. All reagents were obtained from Sigma
(Munich, Germany), except for dimethylmethylene blue dye,
which was obtained from Serva (Heidelberg, Germany). Anti–
-galactosidase (anti–-gal; GAL-13) and anti-FLAG
(BioM2) antibodies were from Sigma, anti-SOX9 antibody
(C-20) was from Santa Cruz Biotechnology (Heidelberg, Ger-
many), and anti–type II collagen antibody (AF-5710) was from
Acris (Hiddenhausen, Germany). Type II collagen contents
were measured with an Arthrogen-CIA native type II collagen
capture enzyme-linked immunosorbent assay (ELISA) kit
(Chondrex, Redmond, WA).
Cartilage and cells. Normal articular cartilage was
obtained from unaffected knee joints that were removed
during tumor surgery in patients ages 67–72 years. OA was
excluded by analysis of Safranin O–stained sections according
to the Mankin scale (Mankin score 1–2) (30). OA cartilage
(Mankin score 7–9) was obtained from joints undergoing total
knee arthroplasty in patients ages 65–78 years. All patients
provided informed consent prior to inclusion in the study.
Explant cultures and chondrocytes were prepared as previously
described (11,24).
Plasmids and rAAV vectors. Plasmid pACP is an
AAV-2–derived vector plasmid from the genomic clone
pSSV9, and pAd8 contains the AAV-2 replication and en-
capsidation functions (31). The rAAV-LacZ plasmid is an
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AAV-2–based vector plasmid carrying the lacZ gene that
encodes -gal under the control of the cytomegalovirus
immediate-early (CMV-IE) promoter (24,25,32). A human
SOX9 (hSOX9) complementary DNA (cDNA; 1.7 kb) ob-
tained from G. Scherer (Institute for Human Genetics and
Anthropology, Albert-Ludwig University, Freiburg, Germany)
(33) was modified to incorporate a FLAG tag on its 5 end.
The hSOX9 fragment was first extracted from pcDNA3-SOX9
(33) by Xho I and Xba I and recloned in pGEM-11Zf()
(Promega, Mannheim, Germany). An hSOX9 fragment was
extracted from the resulting plasmid by Sal I and Hind III and
cloned in pACP. The 5 end of the resulting hSOX9 sequence
was removed by Pst I and Hind III and replaced by a
polymerase chain reaction (PCR) fragment containing the 5
end of hSOX9, where a FLAG tag sequence was incorporated
by PCR using the following primers: 5 F-SOX9 primer
AAAAATCTAGA(Xba I)AAAAGACCCAAGCTGGCTA-
GCCACCATGGACTACAAAGACGATGACGACAAG-
AATCTCCTGGACCCCTTCATGAAGATGACCG and 3
F-SOX9 primer AAAAACTGCAG(Pst I)CGCCTTGAA-
GATGGCGTT. The resulting plasmid vector is rAAV-FLAG-
hSOX9, where the presence of the FLAG-hSOX9 fragment
was confirmed by sequencing. The rAAV vectors were pack-
aged using adenovirus 5 to provide helper functions in combi-
nation with pAd8 (24,25,32). Vector preparations were puri-
fied by dialysis (24,25,32) and titered by real-time PCR
(24,25,32), averaging 1010 functional units/ml.
Gene transfer. Chondrocytes (106) were transduced
with rAAV (300 l) for 2 days and encapsulated in alginate
spheres that were maintained in culture for 26 days to monitor
cell number and viability (25). Explant cultures were trans-
duced by direct application of rAAV to the surface of the
samples (24) and maintained in culture for 10 days.
Analysis of transgene expression. The activity of -gal
was detected by X-Gal staining to determine the transduction
efficiencies (24,25,32,34). Transgene expression was also mon-
itored by indirect immunostaining (25). Transduced explant
cultures were processed for Western blot analysis using the
same amount of proteins (14 g) (35). Expression was revealed
with the use of specific antibodies, horseradish peroxidase–
labeled secondary antibodies (Vector, Gru¨nberg, Germany),
and the ECL Advance Western blotting detection kit (Amer-
sham Biosciences, Freiburg, Germany).
Histologic and immunohistochemical analyses.
Spheres and explant cultures were processed, and paraffin-
embedded sections (5 m) were stained with Safranin O to
detect proteoglycans and with hematoxylin and eosin (H&E)
to detect cells (11,24,25). Type II collagen was detected with a
specific antibody, a biotinylated secondary antibody (Vector),
and the avidinbiotinperoxidase method (Vector) using
diaminobenzidine as the chromogen. Samples were examined
under light microscopy (Olympus BX45 microscope; Ham-
burg, Germany).
Morphometric analyses. Safranin O staining intensities
and cell densities were measured at 3 standardized sites using
SIS AnalySIS (Olympus), Adobe Photoshop (Adobe Systems,
Unterschleissheim, Germany), and Scion Image (Scion, Fred-
erick, MD) software packages. The percentage of Safranin O
staining intensity was calculated as the ratio of positively
stained tissue surface to the total surface of the site evaluated.
Determination of the type II collagen, proteoglycan,
and DNA contents. Solubilized spheres and explant cultures
were digested (25,36) and the type II collagen contents were
determined by ELISA. The proteoglycan contents were de-
tected by binding to dimethylmethylene blue dye (25). The
DNA contents were monitored using Hoechst 33258 dye (25).
Measurements were performed with a GENios spectrophoto-
meter/fluorometer (Tecan, Crailsheim, Germany).
Statistical analysis. Each condition was performed in
triplicate in 3 independent experiments with the spheres and in
triplicate in 2 independent experiments with the explant cul-
tures. Data were obtained by 2 individuals (MC and TT) who
were blinded with regard to the treatment groups. Values are
expressed as the mean  SD. The t-test and Mann-Whitney
rank sum test were used where appropriate. P values less than
0.05 were considered statistically significant.
RESULTS
Expression of a SOX9 gene cassette in human
articular chondrocytes by rAAV transduction in vitro.
The candidate rAAV-FLAG-hSOX9 and control rAAV-
LacZ vectors were first applied to primary cultures of
isolated normal and OA articular chondrocytes. The
rAAV-FLAG-hSOX9 vector carries a human SOX9
cDNA tagged by a FLAG sequence to discriminate
between the endogenous SOX9 (18,22) and the trans-
gene. Chondrocytes were next encapsulated in alginate
spheres and maintained in culture for 26 days. On the
day of encapsulation, -gal activity, restricted to the
control chondrocytes, was already detected and re-
mained present for at least 26 days (results not shown).
Transduction efficiencies were between 76% and 80%,
consistent with previous data using rAAV (24,25). In
contrast, the FLAG tag was detected only in the rAAV-
FLAG-hSOX9–treated chondrocytes (Figure 1). In con-
trast, SOX9 expression was observed in normal and OA
chondrocytes transduced by either vector (results not
shown), which is consistent with the endogenous SOX9
expression in chondrocytes (18).
Stimulation of type II collagen and proteoglycan
synthesis in human articular chondrocytes by SOX9
overexpression. On the day of encapsulation, type II
collagen immunostaining was present in the rAAV-
FLAG-hSOX9–transduced and rAAV-LacZ–
transduced chondrocytes (results not shown), extending
beyond the cell-associated matrix (25). After 26 days, the
immunoreactivity was stronger in the treated chondro-
cytes (Figure 2). As expected (37), the staining was less
intense in OA chondrocytes than in normal chondro-
cytes, but it was stronger in rAAV-FLAG-hSOX–
treated OA chondrocytes than in rAAV-LacZ–treated
control normal chondrocytes.
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Chondrocytes transduced with rAAV-FLAG-
hSOX9 and those transduced with rAAV-LacZ had
similar type II collagen contents on the day of encapsu-
lation (P  0.705 for normal and P  0.168 for OA
chondrocytes) (Table 1). After 26 days, the contents
increased significantly in the rAAV-FLAG-hSOX9–
treated chondrocytes (3.93-fold in normal [P  0.001]
and 3.30-fold in OA [P  0.029] chondrocytes), whereas
the contents did not vary in the rAAV-LacZ–treated
control chondrocytes (P  0.686 for normal and P 
0.886 for OA chondrocytes). OA chondrocytes always
contained less type II collagen than did their normal
counterparts. Remarkably, the contents were signifi-
cantly higher in the treated OA chondrocytes than in the
control normal chondrocytes (2.20-fold; P  0.001).
There was no difference in the proteoglycan
contents of the rAAV-FLAG-hSOX9–transduced and
rAAV-LacZ–transduced chondrocytes on the day of
encapsulation (P  0.940 for normal and P  0.844 for
OA chondrocytes) (Table 1). After 26 days, the amounts
of proteoglycans significantly increased in the treated
chondrocytes (1.73-fold in normal [P  0.029] and
1.70-fold in OA [P 0.001] chondrocytes), whereas they
remained unchanged in the control chondrocytes (P 
0.939 for normal and P  0.912 for OA chondrocytes).
OA chondrocytes always contained less proteoglycans
than the normal counterparts, as has previously been
reported (38). Notably, the contents were significantly
higher in treated OA chondrocytes than in control
normal chondrocytes (1.62-fold; P  0.001).
In contrast to the data for the ECM, the number
of cells in rAAV-FLAG-hSOX9–transduced and rAAV-
LacZ–transduced spheres were not different at any time
point of the analysis (P  0.775 on day 1 and P  1.000
on day 26 in normal chondrocytes; P  0.851 on day 1
and P  1.000 on day 26 in OA chondrocytes) (Table 1).
Over time, a decrease in the cell numbers (for treated
spheres, 2.33-fold [P  0.001] in normal and 2.20-fold
[P  0.029] in OA chondrocytes; for control spheres,
2.37-fold [P 0.001] in normal and 2.12-fold [P 0.029]
in OA chondrocytes) and cell viability (from an overall
mean  SD of 82  3% on day 1 to 35  2% on day 26)
Figure 1. Detection of transgene expression in transduced chondro-
cytes. Normal (A and B) and osteoarthritic (C and D) chondrocytes
were transduced with rAAV-LacZ (A and C) or rAAV-FLAG-hSOX9
(B and D), and transduced spheres (n  9 per condition) were
processed after 26 days to detect the FLAG tag (1:200 dilution).
(Original magnification 100.) Color figure can be viewed in the
online issue, which is available at http://www.arthritisrheum.org
Figure 2. Immunohistochemical detection of type II collagen in trans-
duced chondrocytes. Normal (A and B) and osteoarthritic (C and D)
chondrocytes were transduced with rAAV-LacZ (A and C) or rAAV-
FLAG-hSOX9 (B and D), and transduced spheres (n  9 per
condition) were processed after 26 days to detect type II collagen (1:30
dilution). (Original magnification  200.) Color figure can be viewed
in the online issue, which is available at http://www.arthritisrheum.org
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was noted in both types of spheres. Consistent with this
finding, there was no difference in the cell densities on
H&E-stained histology sections of tissues treated with
the spheres at all time points analyzed, and a decrease in
the densities was seen over time (data not shown). The
DNA contents were similar at all time points analyzed
(P  1.000 on days 1 and 26 in normal and P  0.705 on
day 1 and P  0.670 on day 26 in OA chondrocytes)
(Table 1), and they decreased over time in both types of
spheres (1.48-fold [P  0.001] in normal and 1.40-fold
[P  0.001] in OA chondrocytes).
Expression of the SOX9 gene cassette in human
articular cartilage by direct rAAV application in situ. In
order to evaluate the effects of SOX9 overexpression on
chondrocyte metabolism in a native environment, the
vectors were directly applied to normal and OA cartilage
explant cultures. As early as 5 days after vector applica-
tion, -gal activity, restricted to the control cartilage,
was detected both in the superficial and middle zones
and remained present for at least 10 days (results not
shown). Transduction efficiencies were dose-dependent,
increasing from a mean  SD of 45.3  0.5% with 20 l
of vector to 58.0  0.8% with 50 l of vector in normal
cartilage (1.28-fold; P  0.001) and from 44.5  0.6% to
57.5  0.6% with 20 l and 50 l of vector in OA
cartilage (1.29-fold; P  0.029). In contrast, the FLAG
tag was detected only in rAAV-FLAG-hSOX9–
transduced treated cartilage (results not shown). SOX9
expression, however, was observed in normal and OA
explant cultures where either vector was applied (Figure
3), which is consistent with the previously reported
results of SOX9 expression in cartilage (22). However,
marked differences were noted depending on the vector
applied and the type of cartilage evaluated.
The percentage of cells immunoreactive for the
Figure 3. Detection of transgene expression in transduced cartilage.
Normal (A and B) and osteoarthritic (C and D) cartilage explant
cultures were transduced with 50 l of rAAV-LacZ (A and C) or
rAAV-FLAG-hSOX9 (B and D) and processed after 10 days (n  6
per condition) to detect SOX9 (1:300 dilution). Shown are the middle
zones of the cartilage samples. (Original magnification  100.) SOX9
expression in cartilage was also analyzed by Western blotting (E) of
rAAV-LacZ–transduced normal cartilage (lane 1), rAAV-FLAG-
hSOX9–transduced normal cartilage (lane 2), rAAV-LacZ–
transduced osteoarthritic cartilage (lane 3), and rAAV-FLAG-
hSOX9–transduced osteoarthritic cartilage (lane 4). Molecular weight
markers are shown at the left. Color figure can be viewed in the online
issue, which is available at http://www.arthritisrheum.org
Table 1. Type II collagen, proteoglycan, cell, and DNA contents in transduced chondrocytes
Normal chondrocytes, mean  SD Osteoarthritic chondrocytes, mean  SD
rAAV-LacZ rAAV-FLAG-hSOX9 rAAV-LacZ rAAV-FLAG-hSOX9
Type II collagen, ng/104 cells
Day 1 0.15  0.01 0.15  0.01 0.09 0.01 0.10  0.01
Day 26 0.15  0.01 0.59 0.02* 0.10  0.01 0.33  0.02*
Proteoglycans, g/104 cells
Day 1 4.41  0.09 4.41  0.09 4.00  0.02 4.01 0.01
Day 26 4.20  0.01 7.62 0.02* 3.78  0.01 6.82  0.02*
Cells, 104/sphere
Day 1 0.64  0.02 0.63  0.03 0.53  0.07 0.55 0.10
Day 26 0.27  0.04 0.27  0.05 0.25 0.05 0.25  0.04
DNA, g/104 cells
Day 1 0.31  0.01 0.31 0.01 0.28  0.01 0.28  0.01
Day 26 0.21  0.01 0.21  0.01 0.20  0.01 0.20 0.01
* Significant treatment effect compared with rAAV-LacZ.
162 CUCCHIARINI ET AL
endogenous SOX9 was significantly lower in control OA
cartilage than in normal cartilage (mean  SD 44.8 
0.5% versus 66.6  0.5%; 1.49-fold increase [P 
0.029]), confirming the previously reported decrease in
SOX9 expression in OA cartilage (21,22). Application of
rAAV-FLAG-hSOX9 resulted in a significant increase
in the percentages of cells immunoreactive for SOX9 as
compared with control cartilage due to overexpression
of the transgene (from 66.6  0.5% to 81.7  0.5%;
1.23-fold [P 0.001] in control and from 44.8 0.8% to
65.6  1.7%; 1.46-fold [P  0.001] in OA cartilage).
Importantly, expression of the transgene in OA cartilage
restored the number of SOX9-positive chondrocytes to
levels seen in the control normal cartilage (65.6  1.7%
and 66.6  0.5%; P  1.000).
Western blot analysis of protein extracts from
normal cartilage transduced by either rAAV demon-
strated a single primary SOX9-immunoreactive band of
65 kd (Figure 3E) that was 5 times more intense in
the treated cartilage than in the control cartilage due to
overexpression of the transgene. Similar results were
obtained in OA cartilage, where the band was 3 times
more intense in the treated cartilage. Notably, the
intensity of the immunoreactive band in the treated OA
cartilage was similar to that seen in the control normal
cartilage.
Stimulation of type II collagen synthesis in hu-
man articular cartilage by SOX9 overexpression. Con-
sistent with previous findings (39), immunoreactivity to
type II collagen was uniformly distributed in control
normal cartilage, whereas typical pericellular deposits of
type II collagen, representative of an active synthesis,
were noted in the OA counterpart. Following treatment
with rAAV-FLAG-hSOX9, areas of synthesis became
evident in the superficial and middle zones of normal
cartilage, most particularly when the higher dose of
vector was applied (Figure 4). When this vector was
administered to OA cartilage, the deposits observed in
the control counterpart became even more frequent.
A significant, dose-dependent increase in the
type II collagen content was noted after treatment with
rAAV-FLAG-hSOX9 (Table 2). In normal cartilage, the
content increased 1.76-fold (P  0.001) with 20 l of
vector and increased 2.54-fold (P  0.001) with 50 l as
compared with control treatment (a 1.65-fold dose-
dependent increase; P  0.001). In OA cartilage, the
content increased 1.72-fold (P  0.001) with 20 l of
vector and 1.95-fold (P  0.001) with 50 l (a 1.32-fold
dose-dependent increase; P  0.001). OA cartilage
always contained less type II collagen than did normal
cartilage, as has been described previously (40,41). Most
notably, the content was significantly higher in treated
OA cartilage than in control normal cartilage (1.48-fold
[P  0.001] with 20 l and 1.71-fold [P  0.001] with 50
l of vector), probably due to restored SOX9 expression
levels (see Figure 3).
Stimulation of proteoglycan synthesis in human
articular cartilage by SOX9 overexpression. The inten-
sity of Safranin O staining was significantly higher in the
superficial and middle zones of the cartilage to which
rAAV-FLAG-hSOX9 was applied (see insets in Figure
4). In normal cartilage, the percentage increased 1.16-
fold (from a mean SD of 47.5 0.6% to 55.0 0.8%;
P  0.001) with 20 l of vector and increased 1.51-fold
(from 47.3  1.0% to 71.3  1.0%; P  0.001) with 50
l of vector as compared with control treatment (a
1.30-fold dose-dependent increase; P  0.001). In OA
cartilage, the percentage increased 1.13-fold (from
31.3  1.0% to 35.5  0.6%; P  0.001) with 20 l of
vector and increased 1.51-fold (from 31.3  1.0% to
47.3  1.0%; P  0.001) with 50 l (a 1.33-fold
dose-dependent increase; P  0.001). The staining in-
tensity was always less in OA cartilage than in normal
cartilage, as previously reported (42). Importantly, the
Figure 4. Immunohistochemical detection of type II collagen and
Safranin O and hematoxylin and eosin (H&E) staining in transduced
cartilage. Normal (A and B) and osteoarthritic (C and D) cartilage
explant cultures were transduced with 50 l of rAAV-LacZ (A and C)
or rAAV-FLAG-hSOX9 (B and D) and processed after 10 days (n 
6 per condition) to detect type II collagen (1:50 dilution) and for
staining with Safranin O and H&E (insets). Shown are the middle
zones of the cartilage samples. (Original magnification  40.)
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staining intensity in the treated OA cartilage using the
higher dose of vector was similar to that in the control
normal cartilage (P  0.670).
Treatment with rAAV-FLAG-hSOX9 induced a
significant, dose-dependent increase in the proteoglycan
content of the cartilage (Table 2). In normal cartilage,
the content increased 1.06-fold (P 0.001) with 20 l of
vector and increased 1.20-fold (P  0.001) with 50 l of
vector as compared with control treatment (a 1.13-fold
dose-dependent increase; P  0.001). In OA cartilage,
the values increased 1.05-fold (P 0.001) with 20 l and
1.08-fold (P  0.001) with 50 l (a 1.03-fold dose-
dependent increase; P  0.001) of vector. OA cartilage
always contained less proteoglycans than did normal
cartilage, which is consistent with previous findings (41).
Most important, the content in the OA cartilage treated
with the higher dose of vector was similar to that in the
control normal cartilage (P  0.278), probably due to
restored levels of SOX9 expression (see Figure 3).
Lack of effect of SOX9 overexpression on chon-
drocyte proliferation in human articular cartilage.
There was no difference in the cell densities of the
rAAV-FLAG-hSOX9–transduced and the rAAV-
LacZ–transduced cartilage samples (mean  SD
288  5 versus 287  7 cells/mm2 with 20 l [P  0.869]
and 266  1 versus 267  2 cells/mm2 with 50 l [P 
0.390] of vector in normal cartilage; 286  5 versus
286  6 cells/mm2 with 20 l [P  0.903] and 286  6
versus 286 5 cells/mm2 with 50 l [P 1.000] of vector
in OA cartilage) (Figure 4, insets). Increasing the dose
of the candidate vector had no effect on the cell densities
(P  0.912 in normal and P  0.954 in OA cartilage).
Application of rAAV-FLAG-hSOX9 did not affect the
DNA content in normal (P  0.670 with 20 l and P 
1.000 with 50 l of vector) or OA (P  0.168 with 20 l
and P  0.168 with 50 l of vector) cartilage (Table 2).
Increasing the dose of the vector had no effect on the
content (P  0.670 in normal and P  0.168 in OA
cartilage).
DISCUSSION
Application of candidate therapeutic genes that
restore the ECM in OA articular cartilage is an attrac-
tive approach to balancing the progression of the dis-
ease. In this regard, the effects of external stimuli
provided by the expression of potent chondroprotective
and chondroregenerative factors, such as IL-1Ra or
IGF-1, have been widely evaluated (6,10,11), but com-
plete reproduction of an original articular cartilage
surface has not been achieved thus far with the use of
these agents. Additional treatments might be required to
expand the processes of regeneration in OA cartilage,
such as those based on the use of factors that regulate
chondrogenesis. Transcription factors are good candi-
dates because they have the potential to correct the
phenotype of OA chondrocytes and might thus contrib-
ute to the restoration of cartilage homeostasis.
The identification of a suitable gene vehicle is
particularly important for the treatment of a slow,
progressive disease such as OA, in which the effects of
an agent may be required over prolonged periods of
time. Vectors based on AAV might be advantageous to
achieving this goal because they have the unique ability
to mediate both efficient and stable transgene expres-
sion throughout the entire depth of cartilage (23,24), in
marked contrast with the properties of other classes of
vectors (27). In the present study, we evaluated the
ability of rAAV-mediated SOX9 overexpression to re-
store the cartilage matrix in human OA cartilage as
compared with normal cartilage.
Our data indicate that sustained expression of a
SOX9 gene cassette significantly increased the proteo-
glycan and type II collagen content in 3-dimensional
Table 2. Type II collagen, proteoglycan, and DNA content in transduced cartilage
Normal cartilage, mean  SD Osteoarthritic cartilage, mean  SD
rAAV-LacZ rAAV-FLAG-hSOX9 rAAV-LacZ rAAV-FLAG-hSOX9
20 l 50 l 20 l 50 l 20 l 50 l 20 l 50 l
Type II collagen, ng/mg
dry weight
0.021 
0.001
0.024 
0.001
0.037 
0.001*
0.061 
0.001*
0.018 
0.001
0.021 
0.001
0.031 
0.001*
0.041 
0.001*
Proteoglycans, g/mg
dry weight
2.67 
0.01
2.67 
0.01
2.82 
0.01*
3.20 
0.01*
2.46 
0.01
2.48 
0.01
2.58 
0.01*
2.67 
0.01*
DNA, g/mg dry weight 1.31
0.01
1.31 
0.01
1.31 
0.01
1.31 
0.01
1.25 
0.01
1.26 
0.01
1.26 
0.01
1.25 
0.01
* Significant treatment effect compared with rAAV-LacZ.
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cultures of human normal and OA chondrocytes, con-
sistent with the effects of SOX9 upon the expression of
cartilage matrix components (17–19,43). Notably, the
amount of proteoglycans and type II collagen noted in
the treated OA chondrocytes was significantly higher
than that in the control normal chondrocytes. Applica-
tion of the rAAV-FLAG-hSOX9 vector did not promote
cell proliferation in these systems, which is consistent
with the properties of the transcription factor (26).
These data demonstrate the ability of a therapeutic
candidate to stably restore matrix synthesis in human
OA chondrocytes. Delivery of a SOX9 gene cassette via
adenoviral and retroviral vectors has been shown to
enhance the type II collagen and glycosaminoglycan
content in OA chondrocytes (43,44), but the effects
reported were incomplete in the absence of anabolic
supplements and were noted only over a short period of
time, in contrast with our findings using rAAV. This
might be the result of the persistence of the rAAV
transgenes in their targets (26), in contrast with adeno-
viral or retroviral transgenes that are either less stable or
require cell division prior to expression.
Direct application of rAAV-FLAG-hSOX9 to
human normal and OA cartilage in situ mediated high
levels of transgene expression that was distributed
throughout the thickness of the explant cultures, prob-
ably due to the ability of these small vectors to penetrate
the dense ECM of the cartilage (23,24). The manipula-
tion of vectors such as rAAV might thus be desirable for
introducing candidate genes directly into the targets as
compared with other classes of vectors still used in ex
vivo gene transfer protocols (5,12,45). While no effects
on cell proliferation were seen, expression of the SOX9
gene cassette promoted a significant, dose-dependent
increase in the proteoglycan and type II collagen content
in OA cartilage to levels higher than or similar to those
in the untreated normal cartilage and to depths relevant
for clinical applications (24).
To the best of our knowledge, this is the first
evidence of the ability of SOX9, or of any other thera-
peutic candidate, to compensate for the loss of ECM
components in human OA cartilage. Interestingly, in the
present system, matrix synthesis was enhanced in the
treated OA cartilage as compared with the control
normal cartilage. It remains to be seen whether altered
(different from normal) levels of proteoglycans and type
II collagen caused by SOX9 overexpression influence the
structure of articular cartilage over time. Kypriotou et al
(46) reported that concentrations of SOX9 that were too
high might inhibit type II collagen expression in chon-
drocytes by disturbing the cellular balance between
transcription factors, depending on the stage of cell
differentiation. Regulation of SOX9 expression in these
cells will be critical to the development of an appropriate
gene treatment for OA that does not alter the integrity
of the cartilage. Instead of using the strong CMV-IE
transcription element, transgene expression might be
controlled by regulatable (tetracycline-sensitive) or
tissue-specific (SOX9, type II collagen, cartilage oligo-
meric matrix protein) promoters.
Kypriotou et al (46) also suggested that SOX9
alone might not be sufficient to reorient the chondrocyte
phenotype. Accordingly, Ikeda et al (16) showed that
codelivery of the genes for SOX5 and SOX6 with SOX9
(the SOX trio) was more efficient for inducing a chon-
drocyte phenotype in human mesenchymal stem cells in
vitro as compared with SOX9 treatment alone, although
effects of the SOX trio on OA cartilage have not yet
been reported. Indeed, regeneration of an original car-
tilage surface was not afforded by administration of the
SOX9 vector in the present study. Renewal of a native
phenotype in OA chondrocytes might thus require the
action of more than one intracellular therapeutic agent.
This may be achieved by applying combinations of
rAAV vectors at the same time (47). Restoration of a
normal architecture in OA cartilage may certainly ben-
efit from coapplication of factors that stimulate the
metabolic and proliferative responses of the chondro-
cytes, such as IGF-1 (10,48,49), FGF-2 (11,48), TGF
(49), BMP-7 (12), IL-1Ra (5), and Hsp70 (9). Neverthe-
less, recovery from cartilage degradation using direct
application of gene treatments will be practicable only if
some cartilage surface and resident chondrocytes are
maintained, as in the early stages of OA, while methods
based on the transplantation of genetically modified
cells or progenitors might be desirable for more ad-
vanced cases of the disease.
In summary, the results of this study indicate that
direct, rAAV-mediated overexpression of SOX9 within
human OA cartilage restores the synthesis of proteogly-
cans and type II collagen, 2 key ECM components of the
cartilage. Additional studies in established experimental
models (7,8) will be required in order to evaluate the
effects of SOX9 overexpression in OA cartilage in vivo.
The present findings provide motivation to further de-
velop this therapeutic gene-transfer approach to the
treatment of OA in humans.
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